학술논문
Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody.
Document Type
Article
Source
Subject
*INFLIXIMAB
*TUMOR necrosis factors
*IMMUNOGLOBULINS
*METHOTREXATE
*RHEUMATOID arthritis
*TUMOR treatment
*
*
*
*
*
Language
ISSN
1439-7595
Abstract
Infliximab, an anti-tumor necrosis factor (TNF)-α antibody, was introduced to a 66-year-old woman with methotrexate (MTX)-resistant rheumatoid arthritis (RA). Although the TNF-blocking therapy was successful, she developed noninfectious interstitial pneumonia (IP) after a second infusion of infliximab. In most cases reported previously, infliximab-associated noninfectious IP occurred after a second or third infusion of infliximab, and this type of IP was more fatal in comparison with cases associated with MTX treatment alone. Keeping a sharp lookout on IP development during this period is crucial to the success of infliximab treatment. After MTX discontinuation and steroid pulse therapy, our patient made a dramatic recovery from IP. [ABSTRACT FROM AUTHOR]